Aldeyra Therapeutics Inc

NASDAQ:ALDX   3:59:57 PM EDT
12.50
+0.45 (+3.73%)
Products, Regulatory

Aldeyra Therapeutics Achieves Statistical Significance For Primary Endpoint And All Secondary Endpoints In Phase 3 Invigorate Clinical Trial Of Reproxalap In Allergic Conjunctivitis

Published: 04/27/2021 12:03 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 Invigorate Clinical Trial of Reproxalap in Allergic Conjunctivitis.
Aldeyra Therapeutics Inc - There Were No Observed Safety Or Tolerability Concerns in Invigorate Trial.
Aldeyra Therapeutics Inc - No Observed Adverse Events in Trial Other Than Mild and Transient Instillation Site Discomfort.